These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15806687)

  • 21. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
    Di Marzo V
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
    [No Abstract]   [Full Text] [Related]  

  • 22. [2008: the end of rimonabant's story].
    Paris M
    Ann Pharm Fr; 2009 May; 67(3):167-8. PubMed ID: 19446664
    [No Abstract]   [Full Text] [Related]  

  • 23. Rimonabant: obituary for a wonder drug.
    Boekholdt SM; Peters RJ
    Lancet; 2010 Aug; 376(9740):489-90. PubMed ID: 20709215
    [No Abstract]   [Full Text] [Related]  

  • 24. Rimonabant and progression of atherosclerosis in obese persons.
    Dora JM; Scheffel RS
    JAMA; 2008 Jul; 300(3):280; author reply 280-1. PubMed ID: 18632538
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of rimonabant on weight reduction and cardiovascular risk.
    van Oosten B; Killestein J; Polman Ch
    Lancet; 2005 Jul 30-Aug 5; 366(9483):368-9; author reply 369-70. PubMed ID: 16054933
    [No Abstract]   [Full Text] [Related]  

  • 26. ADAGIO-Lipids gives promises but faces the setbacks.
    Taskinen MR
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):339-40. PubMed ID: 19228609
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of rimonabant on weight reduction and cardiovascular risk.
    Hirschel B
    Lancet; 2005 Jul 30-Aug 5; 366(9483):369; author reply 369-70. PubMed ID: 16054934
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacologic treatment for obesity. Options for today...and tomorrow.
    Lundquist LM; Sirimaturos M; Cannon E
    Adv Nurse Pract; 2006 Aug; 14(8):31-5, 64. PubMed ID: 16972485
    [No Abstract]   [Full Text] [Related]  

  • 29. Withdrawal of Rimonabant--walking the tightrope of 21st century pharmaceutical regulation?
    Taylor D
    Curr Drug Saf; 2009 Jan; 4(1):2-4. PubMed ID: 19256104
    [No Abstract]   [Full Text] [Related]  

  • 30. Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity.
    Patel PN; Pathak R
    Am J Health Syst Pharm; 2007 Mar; 64(5):481-9. PubMed ID: 17322160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Endocannabinoid and endocannabinoid receptor antagonists].
    Heinzl S
    Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333
    [No Abstract]   [Full Text] [Related]  

  • 32. [Rimonabant--a panacea for patients with metabolic syndrome?].
    Broncel M; Koziróg M
    Pol Arch Med Wewn; 2006 Aug; 116(2):787-93. PubMed ID: 17424926
    [No Abstract]   [Full Text] [Related]  

  • 33. [Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects].
    Wettermark B; Raaschou P; Forslund T; Hjemdahl P
    Lakartidningen; 2007 Dec; 104(51-52):3879-81. PubMed ID: 18232530
    [No Abstract]   [Full Text] [Related]  

  • 34. Another pill for weight reduction.
    Conti CR
    Clin Cardiol; 2005 Feb; 28(2):59-60. PubMed ID: 15757073
    [No Abstract]   [Full Text] [Related]  

  • 35. End of the line for cannabinoid receptor 1 as an anti-obesity target?
    Jones D
    Nat Rev Drug Discov; 2008 Dec; 7(12):961-2. PubMed ID: 19043439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Drug treatment of obesity].
    Svendsen OL; Toubro S; Breum L; Bruun JM; Astrup AV
    Ugeskr Laeger; 2006 Jan; 168(2):163-7. PubMed ID: 16403342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.
    Bifulco M; Grimaldi C; Gazzerro P; Pisanti S; Santoro A
    Mol Pharmacol; 2007 Jun; 71(6):1445-56. PubMed ID: 17327463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
    Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C
    Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rimonabant improves weight and glycaemic control: first oral antidiabetic therapy in newly diagnosed type 2 diabetics.
    Cardiovasc J Afr; 2008; 19(5):282-3. PubMed ID: 18997994
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.
    Christensen R; Kristensen PK; Bartels EM; Bliddal H; Astrup A
    Lancet; 2007 Nov; 370(9600):1706-13. PubMed ID: 18022033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.